Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial

A Pardanani, C Harrison, JE Cortes, F Cervantes… - JAMA …, 2015 - jamanetwork.com
Importance Myelofibrosis (MF) is aBCR-ABL–negative myeloproliferative neoplasm
characterized by anemia, splenomegaly, debilitating constitutional symptoms, and …
被引用次数：469 相关文章

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial

A Pardanani, C Harrison, JE Cortes… - JAMA …, 2015 - pubmed.ncbi.nlm.nih.gov
Importance Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm
characterized by anemia, splenomegaly, debilitating constitutional symptoms, and …

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial

A Pardanani, C Harrison, JE Cortes… - JAMA …, 2015 - irinsubria.uninsubria.it
Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by
anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival …

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial.

A Pardanani, C Harrison, JE Cortes, F Cervantes… - JAMA …, 2015 - europepmc.org
Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A
Randomized Clinical Trial. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial

A Pardanani, C Harrison, JE Cortes, F Cervantes… - JAMA, 2015 - jamanetwork.com
OBJECTIVE To evaluate the efficacy and safety of fedratinib therapy in patients with primary
or secondary (post–polycythemia vera or post–essential thrombocythemia) MF. DESIGN …

Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial

A Pardanani, C Harrison, JE Cortes, F Cervantes… - JAMA …, 2015 - flore.unifi.it
Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm characterized by
anemia, splenomegaly, debilitating constitutional symptoms, and shortened survival …

Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial

A Pardanani, C Harrison, JE Cortes… - JAMA …, 2015 - augusta.elsevierpure.com
Importance: Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm
characterized by anemia, splenomegaly, debilitating constitutional symptoms, and …
[HTML] sodiumchannel-signal.com

[HTML][HTML] Sodium Channel Signal

A Pardanani, C Harrison, JE Cortes… - …, 2015 - sodiumchannel-signal.com
OBJECTIVE To evaluate the efficacy and safety of fedratinib therapy in patients with primary
or secondary (post–polycythemia vera or post–essential thrombocythemia) MF. DESIGN …
[PDF] academia.edu

[PDF][PDF] Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis A Randomized Clinical Trial

A Pardanani, C Harrison, JE Cortes, F Cervantes… - JAMA, 2015 - academia.edu
OBJECTIVE To evaluate the efficacy and safety of fedratinib therapy in patients with primary
or secondary (post–polycythemia vera or post–essential thrombocythemia) MF. DESIGN …

Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: A randomized clinical trial

A Pardanani, C Harrison, JE Cortes… - JAMA …, 2015 - mayoclinic.elsevierpure.com
Importance: Myelofibrosis (MF) is a BCR-ABL-negative myeloproliferative neoplasm
characterized by anemia, splenomegaly, debilitating constitutional symptoms, and …